Header Logo

Connection

STEVEN JAY FRANK to Radiotherapy Dosage

Back to Details
This is a "connection" page, showing publications STEVEN JAY FRANK has written about Radiotherapy Dosage.
STEVEN JAY FRANK
Connection Strength
3.574
Radiotherapy Dosage
  1. Comprehensive insights on the underlying potential and advantage of proton therapy over intensity-modulated photon radiation therapy as highlighted in a wide real world data analysis. Radiother Oncol. 2024 Apr; 193:110122.
    View in: PubMed
    Score: 0.136
  2. Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry. Brachytherapy. 2023 Nov-Dec; 22(6):822-832.
    View in: PubMed
    Score: 0.132
  3. Computer-aided segmentation on MRI for prostate radiotherapy, Part I: Quantifying human interobserver variability of the prostate and organs at risk and its impact on radiation dosimetry. Radiother Oncol. 2022 04; 169:124-131.
    View in: PubMed
    Score: 0.117
  4. Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Curr Treat Options Oncol. 2021 06 04; 22(6):54.
    View in: PubMed
    Score: 0.113
  5. Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. Radiother Oncol. 2021 07; 160:32-39.
    View in: PubMed
    Score: 0.112
  6. The American Brachytherapy Society prostate brachytherapy LDR/HDR simulation workshops: Hands-on, step-by-step training in the process of quality assurance. Brachytherapy. 2020 Nov - Dec; 19(6):787-793.
    View in: PubMed
    Score: 0.108
  7. Fully Balanced SSFP Without an Endorectal Coil for Postimplant QA of MRI-Assisted Radiosurgery (MARS) of Prostate Cancer: A Prospective Study. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):614-625.
    View in: PubMed
    Score: 0.108
  8. Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy. 2020 Sep - Oct; 19(5):574-583.
    View in: PubMed
    Score: 0.106
  9. Evaluation of the accuracy of deformable image registration on MRI with a physical phantom. J Appl Clin Med Phys. 2020 Jan; 21(1):166-173.
    View in: PubMed
    Score: 0.102
  10. MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy. Brachytherapy. 2020 Jan - Feb; 19(1):38-42.
    View in: PubMed
    Score: 0.102
  11. Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Semin Radiat Oncol. 2018 04; 28(2):108-113.
    View in: PubMed
    Score: 0.091
  12. Proton Therapy for Head and Neck Cancers. Semin Radiat Oncol. 2018 01; 28(1):53-63.
    View in: PubMed
    Score: 0.089
  13. Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. Radiother Oncol. 2017 06; 123(3):401-405.
    View in: PubMed
    Score: 0.085
  14. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. Med Dosim. 2016; 41(3):189-94.
    View in: PubMed
    Score: 0.079
  15. Intensity Modulated Proton Therapy for Head and Neck Tumors: Gilding the Lily or Holy Grail? Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):37-39.
    View in: PubMed
    Score: 0.079
  16. Proton therapy for nasopharyngeal carcinoma. Chin Clin Oncol. 2016 Apr; 5(2):25.
    View in: PubMed
    Score: 0.079
  17. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):360-367.
    View in: PubMed
    Score: 0.078
  18. Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. Head Neck. 2016 04; 38 Suppl 1:E1886-95.
    View in: PubMed
    Score: 0.077
  19. Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. Head Neck. 2016 04; 38 Suppl 1:E1472-80.
    View in: PubMed
    Score: 0.077
  20. A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):344-352.
    View in: PubMed
    Score: 0.075
  21. Magnetic resonance image guided brachytherapy. Semin Radiat Oncol. 2014 Jul; 24(3):181-91.
    View in: PubMed
    Score: 0.070
  22. Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):846-53.
    View in: PubMed
    Score: 0.069
  23. Dosimetric influence of seed spacers and end-weld thickness for permanent prostate brachytherapy. Brachytherapy. 2014 May-Jun; 13(3):304-10.
    View in: PubMed
    Score: 0.066
  24. An MRI-based dose--reponse analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial. Brachytherapy. 2013 May-Jun; 12(3):210-6.
    View in: PubMed
    Score: 0.064
  25. Magnetic resonance imaging-based treatment planning for prostate brachytherapy. Brachytherapy. 2013 Jan-Feb; 12(1):30-7.
    View in: PubMed
    Score: 0.061
  26. Preoperative treatment planning with intraoperative optimization can achieve consistent high-quality implants in prostate brachytherapy. Med Dosim. 2012; 37(4):387-90.
    View in: PubMed
    Score: 0.060
  27. Displacement of periurethral stranded seeds and its dosimetric consequences in prostate brachytherapy. Brachytherapy. 2011 Sep-Oct; 10(5):401-8.
    View in: PubMed
    Score: 0.055
  28. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era? Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):623-7.
    View in: PubMed
    Score: 0.045
  29. Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):813-20.
    View in: PubMed
    Score: 0.045
  30. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007 Jun; 177(6):2151-6; discussion 2156.
    View in: PubMed
    Score: 0.043
  31. Technology insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. Nat Clin Pract Oncol. 2005 Oct; 2(10):526-33.
    View in: PubMed
    Score: 0.038
  32. The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies. JAMA Oncol. 2024 Mar 01; 10(3):289-290.
    View in: PubMed
    Score: 0.034
  33. Treatment planning for lung cancer: traditional homogeneous point-dose prescription compared with heterogeneity-corrected dose-volume prescription. Int J Radiat Oncol Biol Phys. 2003 Aug 01; 56(5):1308-18.
    View in: PubMed
    Score: 0.033
  34. Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial. J Clin Oncol. 2023 08 20; 41(24):4035-4044.
    View in: PubMed
    Score: 0.032
  35. A deep learning-based approach for statistical robustness evaluation in proton therapy treatment planning: a feasibility study. Phys Med Biol. 2023 04 26; 68(9).
    View in: PubMed
    Score: 0.032
  36. Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study. Radiother Oncol. 2023 07; 184:109672.
    View in: PubMed
    Score: 0.032
  37. Intensity modulated proton arc therapy via geometry-based energy selection for ependymoma. J Appl Clin Med Phys. 2023 Jul; 24(7):e13954.
    View in: PubMed
    Score: 0.032
  38. Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional study. Radiother Oncol. 2023 06; 183:109599.
    View in: PubMed
    Score: 0.032
  39. Adaptation and dosimetric commissioning of a synchrotron-based proton beamline for FLASH experiments. Phys Med Biol. 2022 08 05; 67(16).
    View in: PubMed
    Score: 0.031
  40. Impact of RBE variations on risk estimates of temporal lobe necrosis in patients treated with intensity-modulated proton therapy for head and neck cancer. Acta Oncol. 2022 Feb; 61(2):215-222.
    View in: PubMed
    Score: 0.029
  41. Mixed Effect Modeling of Dose and Linear Energy Transfer Correlations With Brain Image Changes After Intensity Modulated Proton Therapy for Skull Base Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2021 11 01; 111(3):684-692.
    View in: PubMed
    Score: 0.028
  42. Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer. 2021 04 15; 127(8):1228-1237.
    View in: PubMed
    Score: 0.027
  43. Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head Neck. 2020 11; 42(11):3326-3335.
    View in: PubMed
    Score: 0.027
  44. Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. Radiother Oncol. 2020 10; 151:119-125.
    View in: PubMed
    Score: 0.027
  45. Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiother Oncol. 2020 05; 146:200-204.
    View in: PubMed
    Score: 0.026
  46. Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. Radiother Oncol. 2020 06; 147:64-74.
    View in: PubMed
    Score: 0.026
  47. Transitioning from measurement-based to combined patient-specific quality assurance for intensity-modulated proton therapy. Br J Radiol. 2020 Mar; 93(1107):20190669.
    View in: PubMed
    Score: 0.025
  48. Multiple-CT optimization: An adaptive optimization method to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers. Radiother Oncol. 2020 01; 142:124-132.
    View in: PubMed
    Score: 0.025
  49. Quantifying the accuracy of deformable image registration for cone-beam computed tomography with a physical phantom. J Appl Clin Med Phys. 2019 Oct; 20(10):92-100.
    View in: PubMed
    Score: 0.025
  50. Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. Radiat Oncol. 2019 Aug 19; 14(1):148.
    View in: PubMed
    Score: 0.025
  51. Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer. Oral Oncol. 2019 01; 88:66-74.
    View in: PubMed
    Score: 0.024
  52. MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life. Radiother Oncol. 2018 12; 129(3):554-560.
    View in: PubMed
    Score: 0.023
  53. A methodology to investigate the impact of image distortions on the radiation dose when using magnetic resonance images for planning. Phys Med Biol. 2018 04 05; 63(8):085005.
    View in: PubMed
    Score: 0.023
  54. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer. 2018 04 01; 124(7):1415-1427.
    View in: PubMed
    Score: 0.022
  55. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. Technol Cancer Res Treat. 2017 12; 16(6):1194-1201.
    View in: PubMed
    Score: 0.022
  56. Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A "Game Changer" for Prostate Treatment? Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):361-373.
    View in: PubMed
    Score: 0.022
  57. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol. 2016 08; 39(4):368-73.
    View in: PubMed
    Score: 0.020
  58. Quantitative analysis of treatment process time and throughput capacity for spot scanning proton therapy. Med Phys. 2016 Jul; 43(7):3975.
    View in: PubMed
    Score: 0.020
  59. Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose-response characterization of quantitative signal kinetics. Radiother Oncol. 2016 Feb; 118(2):315-22.
    View in: PubMed
    Score: 0.019
  60. Evaluation of the MIM Symphony treatment planning system for low-dose-rate- prostate brachytherapy. J Appl Clin Med Phys. 2015 09 08; 16(5):62?75.
    View in: PubMed
    Score: 0.019
  61. Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. Head Neck. 2016 04; 38 Suppl 1:E925-33.
    View in: PubMed
    Score: 0.019
  62. Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiother Oncol. 2015 Mar; 114(3):367-72.
    View in: PubMed
    Score: 0.018
  63. ACR Appropriateness Criteria? Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
    View in: PubMed
    Score: 0.017
  64. Preliminary evaluation of multifield and single-field optimization for the treatment planning of spot-scanning proton therapy of head and neck cancer. Med Phys. 2013 Aug; 40(8):081709.
    View in: PubMed
    Score: 0.016
  65. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. Med Phys. 2013 May; 40(5):051711.
    View in: PubMed
    Score: 0.016
  66. A novel dose-based positioning method for CT image-guided proton therapy. Med Phys. 2013 May; 40(5):051714.
    View in: PubMed
    Score: 0.016
  67. PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization. Med Phys. 2013 Feb; 40(2):021709.
    View in: PubMed
    Score: 0.016
  68. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46.
    View in: PubMed
    Score: 0.016
  69. Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):941-7.
    View in: PubMed
    Score: 0.015
  70. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):693-9.
    View in: PubMed
    Score: 0.015
  71. Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer. 2012 Jul; 48(11):1664-71.
    View in: PubMed
    Score: 0.015
  72. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J. 2012 Jan-Feb; 18(1):1-8.
    View in: PubMed
    Score: 0.015
  73. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1310-7.
    View in: PubMed
    Score: 0.013
  74. Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer. Int J Radiat Oncol Biol Phys. 2010 Jun 01; 77(2):455-61.
    View in: PubMed
    Score: 0.012
  75. Variations in proton scanned beam dose delivery due to uncertainties in magnetic beam steering. Med Phys. 2009 Aug; 36(8):3693-702.
    View in: PubMed
    Score: 0.012
  76. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 15; 67(4):1059-65.
    View in: PubMed
    Score: 0.010
  77. Heterogeneous planning for homogeneous protocols. Med Dosim. 2004; 29(2):80-4.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.